@OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

 Worldwide
oncupdates.com/
Joined November 2024
  • Tweets2.1K
  • Following751
  • Followers1K
217Media
⭐️ #SOHO26: OPTIC ✅ Median EFS: 57.2 mo (45 mg → 15 mg) vs 30.6 mo (30 mg) vs 20.6 mo (15 mg) ✅ Response-based de-escalation to 15 mg after ≤1% BCR::ABL1 preserved responses while lowering AOE rates over time #HemOnc #leusm #MedX @sawyer_bawek #MedEd oncupdates.com/article/soho-…

OPTIC 5-Year Update: Ponatinib Dose Optimization in CML - OncUpdates

Explore 5-year OPTIC trial results on ponatinib dose optimization in chronic myeloid leukemia, including event-free survival, molecular response, and long-term safety.

oncupdates.com
1
3
143
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 20
🚨 @FDA approval 🚨 ✅ Dostarlimab for untreated Stage II/III MSI-H/dMMR locally advanced #RectalCancer 👉Based on Ph II AZUR-1 (n=154): ⭐️ 500 mg IV Q3W × 9 cycles ✅ 71% received IO alone ✅ Sustained cCR at 12 mos: 47% by ICR #OncTwitter #gism #GIOnc #MedTwitter #FDA
Oncology Brothers
@OncBrothersOct 19
Dostarlimab (IV q3 wks, 9 cycles) is now @FDA ✅ for locally advanced (Stg II/III) MSI-H/dMMR rectal cancer off Ph II AZUR-1 study: - 71% got IO alone (no additional Rx) - Clinical CR for 12 mos: 47% (no progression at 26.3mos median f/u) - Surgery/Chemo free option! #gism
2
3
283
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 20
🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review! 👀 Here is a sneak peek of your board review day! 🗓️ In-person w/@OncBrothers + @TwoOncDocs 🔗 Register: bit.ly/hemeboards #OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow
9
1
9
1,437
⭐️ Selecting Patients With #CML for #Ponatinib 🎙️ @FadiHaddad_MD + Dr. Deininger 🗣️ #OPTIC ✅ 45 mg → 15 mg after ≤1% BCR::ABL1: ✅ Risk is a continuum, factor comorbidities, T315I, disease tempo & goals #HemOnc #OncTwitter #leusm #MedEd #SOHO26 🎥👇 oncupdates.com/video-podcast…

How to Select Patients With CML for Ponatinib Therapy - OncUpdates

Fadi Haddad, MD, and Michael W. Deininger, MD, discuss how long-term data from the phase 2 OPTIC trial help guide patient selection for ponatinib therapy.

oncupdates.com
1
77
Excited to join the Clinicals to Exam – Oncology Board Review during #ASH2026 in New Orleans on December 11! Looking forward to strengthening my clinical knowledge, gaining valuable insights, and connecting with fellow hematology/oncology professionals! #HemeOnc #Oncology #MedEd @OncUpdates @OncBrothers @TwoOncDocs #hematology OncologyBrothers.regfox.com/…

Clinicals to Exam at ASH

oncologybrothers.regfox.com
1
3
11
1,020
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 19
⭐️ Ep. 1: Tissue vs Liquid Biopsy Testing in HR+ mBC 🎙️ @OncBrothers + @VKaklamani @KalinskyKevin @DrWGradishar & Dr. Nazarullah discuss when and how to use tissue vs ctDNA in HR+/HER2− metastatic breast cancer. #bcsm #BreastCancer #OncTwitter 🎥 👇 oncupdates.com/video-podcast…

Tissue vs. Liquid Biopsy Testing in HR+ mBC - OncUpdates

Alia Nazarulla, MD; Kevin Kalinsky, MD, MS, FASCO; and Virginia Kaklamani, MD, DSc, discuss tissue and liquid biopsy testing in metastatic breast cancer.

oncupdates.com
6
7
655
🚨 @FDA approval 🚨 ✅ Dostarlimab for untreated Stage II/III MSI-H/dMMR locally advanced #RectalCancer 👉Based on Ph II AZUR-1 (n=154): ⭐️ 500 mg IV Q3W × 9 cycles ✅ 71% received IO alone ✅ Sustained cCR at 12 mos: 47% by ICR #OncTwitter #gism #GIOnc #MedTwitter #FDA
Oncology Brothers
@OncBrothersOct 19
Dostarlimab (IV q3 wks, 9 cycles) is now @FDA ✅ for locally advanced (Stg II/III) MSI-H/dMMR rectal cancer off Ph II AZUR-1 study: - 71% got IO alone (no additional Rx) - Clinical CR for 12 mos: 47% (no progression at 26.3mos median f/u) - Surgery/Chemo free option! #gism
2
3
283
🩸Excellent opportunity for fellows at #ASH26! The @ASCO oncology board review session was excellent, highly recommend 🙌 #OncTwitter #HemOnc #MedTwitter #MedX #BoardReview #MedEd @HemOncFellows @ASH_hematology @hemeoncfellow @IMG_Oncologists
OncUpdates
@OncUpdatesOct 20
🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review! 👀 Here is a sneak peek of your board review day! 🗓️ In-person w/@OncBrothers + @TwoOncDocs 🔗 Register: bit.ly/hemeboards #OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow
4
8
783
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 19
⭐️ 5-Year EFS Update from #OPTIC at #SOHO26 🎙️ @FadiHaddad_MD w/Dr. Deininger on response-based #ponatinib dosing in CP-#CML ✅ 45 mg start → best EFS (57.2 mo overall; 55.2 mo in T315I) #CMLsm #HemOnc #OncTwitter #MedTwitter #leusm #MedX #MedEd 🎥👇 oncupdates.com/video-podcast…

5-Year EFS Update From OPTIC - OncUpdates

Fadi Haddad, MD, and Michael W. Deininger, MD, discuss the 5-year EFS update from the OPTIC trial presented at SOHO 2026.

oncupdates.com
1
2
238
🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review! 👀 Here is a sneak peek of your board review day! 🗓️ In-person w/@OncBrothers + @TwoOncDocs 🔗 Register: bit.ly/hemeboards #OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow
9
1
9
1,437
⭐️ Ep. 1: Tissue vs Liquid Biopsy Testing in HR+ mBC 🎙️ @OncBrothers + @VKaklamani @KalinskyKevin @DrWGradishar & Dr. Nazarullah discuss when and how to use tissue vs ctDNA in HR+/HER2− metastatic breast cancer. #bcsm #BreastCancer #OncTwitter 🎥 👇 oncupdates.com/video-podcast…

Tissue vs. Liquid Biopsy Testing in HR+ mBC - OncUpdates

Alia Nazarulla, MD; Kevin Kalinsky, MD, MS, FASCO; and Virginia Kaklamani, MD, DSc, discuss tissue and liquid biopsy testing in metastatic breast cancer.

oncupdates.com
6
7
655
Dostarlimab (IV q3 wks, 9 cycles) is now @FDA ✅ for locally advanced (Stg II/III) MSI-H/dMMR rectal cancer off Ph II AZUR-1 study: - 71% got IO alone (no additional Rx) - Clinical CR for 12 mos: 47% (no progression at 26.3mos median f/u) - Surgery/Chemo free option! #gism
Dr. Cathy Eng
@CathyEngMDJul 1
Replying to @AndreaCercek
@AndreaCercek 🤩announced at #ESMOGI2026 phase 2 AZUR-1 will be presented at @myESMO #ESMO2026 which was created to validate her original single center Dostarlimab data in #rectal #cancer. Looking forward to the results! #CancerResearch @GSK_US @OncoAlert
24
6
60
8,162
Clinical Foundation: From the basics to the most mature data. Here we touched on the logistics, holding/bridging therapies, and AEs for CAR-Ts with @sghmd and @End_myeloma! Full 🗣️: ⭐️ oncbrothers.com/cf-car-t ⭐️ “Oncology Brothers” podcast @OncUpdates #HemeTwitter
8
1
20
1,939
⭐️ 5-Year EFS Update from #OPTIC at #SOHO26 🎙️ @FadiHaddad_MD w/Dr. Deininger on response-based #ponatinib dosing in CP-#CML ✅ 45 mg start → best EFS (57.2 mo overall; 55.2 mo in T315I) #CMLsm #HemOnc #OncTwitter #MedTwitter #leusm #MedX #MedEd 🎥👇 oncupdates.com/video-podcast…

5-Year EFS Update From OPTIC - OncUpdates

Fadi Haddad, MD, and Michael W. Deininger, MD, discuss the 5-year EFS update from the OPTIC trial presented at SOHO 2026.

oncupdates.com
1
2
238
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 17
⭐️Emerging therapies & evolving strategies in #SCLC @OncBrothers 🗣️ w/ @drshieldsmd + @Latinamd ✅ Tarlatamab emerging as important 2L option ✅ #MAVERICK: MRI surveillance preferred over PCI 🗣️ ADCs may further expand options #lcsm #OncTwitter #HemOnc oncupdates.com/video-podcast…

Small Cell Lung Cancer: Emerging Treatments and Care - OncUpdates

Drs. Misty Shields and Estelamari Rodriguez explore emerging small cell lung cancer treatments, including trilaciclib, tarlatamab, MRI surveillance, and antibody-drug conjugates, with insights from...

oncupdates.com
2
1
8
1,435
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 14
#WCLC26🗣️@OncBrothers @christine_lovly #MAVERICK:MRI alone→⬆️ CFFS #ADAURA:8-yr OS ⬆️ with adj osimertinib #HARMONi:OS ⬆️ with ivo+chemo post-TKI EGFRm #PAPILLON:OS supports 1L ami+chemo in EGFR ex20 #DESTINYLung04:T-DXd ↑PFS v pembro+chemo #OncTwitter oncupdates.com/video-podcast…

SCLC and NSCLC Highlights From WCLC 2026 - OncUpdates

Christine Lovly, MD, PhD, FASCO, of City of Hope, reviews presentations at WCLC 2026 from the MAVERICK, ADAURA, HARMONi, PAPILLON, and DESTINY-Lung04 trials.

oncupdates.com
1
2
6
471
Thanks for the invitation @OncBrothers to discuss latest data on SCLC with the amazing @drshieldsmd @SclcSMASHERS @OncUpdates
OncUpdates
@OncUpdatesOct 17
⭐️Emerging therapies & evolving strategies in #SCLC @OncBrothers 🗣️ w/ @drshieldsmd + @Latinamd ✅ Tarlatamab emerging as important 2L option ✅ #MAVERICK: MRI surveillance preferred over PCI 🗣️ ADCs may further expand options #lcsm #OncTwitter #HemOnc oncupdates.com/video-podcast…

Small Cell Lung Cancer: Emerging Treatments and Care - OncUpdates

Drs. Misty Shields and Estelamari Rodriguez explore emerging small cell lung cancer treatments, including trilaciclib, tarlatamab, MRI surveillance, and antibody-drug conjugates, with insights from...

oncupdates.com
4
20
1,097
⭐️Emerging therapies & evolving strategies in #SCLC @OncBrothers 🗣️ w/ @drshieldsmd + @Latinamd ✅ Tarlatamab emerging as important 2L option ✅ #MAVERICK: MRI surveillance preferred over PCI 🗣️ ADCs may further expand options #lcsm #OncTwitter #HemOnc oncupdates.com/video-podcast…

Small Cell Lung Cancer: Emerging Treatments and Care - OncUpdates

Drs. Misty Shields and Estelamari Rodriguez explore emerging small cell lung cancer treatments, including trilaciclib, tarlatamab, MRI surveillance, and antibody-drug conjugates, with insights from...

oncupdates.com
2
1
8
1,435
OncUpdates retweeted
OncUpdates
@OncUpdatesOct 16
🤔Headed to #ASH26? Join for a FREE board review! 🗓️ In-person w/@OncBrothers + @TwoOncDocs 📅 Friday, Dec 11th 📍 Common House,New Orleans 🔗 Register: bit.ly/hemeboards #OncTwitter #HemOnc #MedX #MedTwitter #ASH #MedEd @HemOncFellows @hemeoncfellow @ASH_hematology
8
10
739
🚨 ESMO 2026: A new treatment algorithm for localized gastric & oesophageal cancer! 🔹 Oesophageal SCC: CROSS → Surgery → Adjuvant nivolumab (if residual disease) 🔹 Gastric/GEJ adenocarcinoma: Perioperative D-FLOT + durvalumab maintenance is now preferred. 🔹 Early-stage disease: Endoscopic or surgical resection. 🔹 Unresectable/unfit: Definitive chemoradiotherapy. The key shift: Immunotherapy is now integrated into curative-intent treatment for selected patients. #ESMO2026 #GastricCancer #EsophagealCancer @ASCO @oncoalert
40
108
5,637
Load more